Since signs of low pancreatic expression levels of Zip14 have been demonstrated in T2D, enhanced Zip14 activity could potentially serve as a future pharmacological target in the treatment of beta-cell dysfunction. This evidence concerns the gene SLC39A14 and type 2 diabetes mellitus.